Survivors of childhood cancer often do not know enough about their diagnosis and treatment to help prevent related health problems as adults, a study suggests. Read more: https://utdailybeacon.com/131065/news/adults-ignorant-of-medical-history/

A large cohort study shows that meningiomas develop years later in a significant minority of survivors, with higher risks linked to treatment at earlier ages, radiation exposure, and certain chemotherapies. Read more: https://www.emjreviews.com/neurology/news/study-tracks-risk-of-meningiomas-in-childhood-cancer-survivors/

When a child is diagnosed with cancer, parents often want to understand why. For those with pediatric thyroid carcinoma, a rare disease, that question has long gone unanswered. However, a new study is changing that narrative, revealing hidden genetic clues that may help explain why the disease occurs in some children. Read more: https://www.stjude.org/research/progress/2025/genetic-clues-unlock-mystery-of-pediatric-thyroid-cancer.html

St. Jude Children's Research Hospital scientists identified a promising combination approach to treat a rare, but catastrophic pediatric brain cancer called atypical teratoid rhabdoid tumor (ATRT). Read more: https://www.news-medical.net/news/20251216/Combination-therapy-shows-promise-to-treat-a-rare-catastrophic-pediatric-brain-cancer.aspx

Children with a rare form of cancer called neuroblastoma which hasn’t responded to initial treatment or that has relapsed may benefit from adding antibody treatment to usual chemotherapy, according to new results from a clinical trial. Read more: https://www.birmingham.ac.uk/news/2025/adding-antibody-treatment-to-chemo-boosts-outcomes-for-children-with-rare-cancer

Removing etoposide from frontline induction chemotherapy did not appear to negatively affect key outcomes for patients with pediatric acute myeloid leukemia (AML), according to recent findings from a Children’s Oncology Group (COG) clinical trial presented at the ASH Annual Meeting 2025. Read more: https://www.cancertherapyadvisor.com/reports/etoposide-safely-eliminated-pediatric-acute-myeloid-leukemia/

A unique facility in Melbourne containing hundreds of childhood cancer tissue samples has produced a first-of-its-kind catalog of pediatric cancers to help identify how the immune system can target each one. Read more: https://medicalxpress.com/news/2025-12-childhood-cancer-door-pediatric-immunotherapy.html#goog_rewarded

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same leukemia-causing gene mutation can have dramatically different outcomes: it depends on when in development the mutation first occurs.   Read more: https://www.mountsinai.org/about/newsroom/2025/mount-sinai-study-finds-childhood-leukemia-aggressiveness-depends-on-timing-of-genetic-mutation

Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL) – the most common pediatric cancer – develop serious financial difficulties during their child’s treatment, including losing 25% or more of their household income and struggling to cover the costs of basic living expenses such as housing, food, and utilities. Read more: https://www.eurekalert.org/news-releases/1108761

A discovery from Australian researchers could lead to better treatment for children with neuroblastoma, a cancer that currently claims 9 out of 10 young patients who experience recurrence. The team at the Garvan Institute of Medical Research in Sydney, Australia, found a drug combination that can bypass the cellular defenses these tumors develop that lead to relapse. Read more: https://medicalxpress.com/news/2025-11-drug-combination-sidesteps-resistance-aggressive.html